Literature DB >> 12469003

Sequential changes in the plasma concentration of risperidone following intentional overdose.

Hirofumi Nishikage1, Takeshi Nakanishi, Yoshihiro Takamitsu, Junnosuke Yamamoto.   

Abstract

Risperidone (RIS) is a novel antipsychotic agent whose pharmacokinetics have yet to be fully determined. In particular, little is known about RIS following an overdose. We report the pharmacokinetics following ingestion of a high dose of RIS by serially measuring the plasma concentration in two patients. These patients were admitted in a comatose state following an intentional overdose of RIS; all patients survived. In the first patient, 14 mg of RIS had been ingested 2 hr before the first blood sample was obtained. The second patient ingested an estimated 90 mg of RIS. Seven time-points were determined. The maximum concentration of unaltered RIS was 325 ng/mL and that of the principal metabolite (9-hydroxy-risperidone: 9-OH RIS) was 139 ng/mL. By plotting the time-concentration curve for the active fraction (RIS plus 9-OH-RIS) in the first and second patients, the half-life of RIS following overdose was determined and was approximately 12.7 hr and 17.8 hr, respectively. These values are similar to the half-life of RIS in healthy individuals ingesting a therapeutic dose. Two patients did not developed parkinsonism nor dystonia, and were discharged without sequelae.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12469003     DOI: 10.1097/00002826-200211000-00005

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

1.  Correlation of hair risperidone concentration and serum level among patients with schizophrenia.

Authors:  Xiujia Sun; Lihua Wang; Fuzhong Yang; Juanjuan Ren; Ping Jiang; Hongmei Liu; Huafang Li; Chunbo Li; Chen Zhang
Journal:  Gen Psychiatr       Date:  2019-02-20

Review 2.  A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Authors:  Hock Heng Tan; Jason Hoppe; Kennon Heard
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.